Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
NCT02117219
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
67
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndrome
Interventions
BIOLOGICAL:
MEDI4736 Evaluate MEDI4736 in MDS
DRUG:
VIDAZA
BIOLOGICAL:
tremelimumab
Sponsor
MedImmune LLC